Skip to main content

Advertisement

SpringerLink
Log in

Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Undifferentiated connective tissue disease (UCTD) is a unique clinical entity, a potential forerunner of well-established systemic autoimmune/rheumatic diseases. UCTD is characterized by the presence of various clinical symptoms, as well as a diverse repertoire of autoantibodies, resembling systemic autoimmune diseases. Since approximately one third of these patients consequently transform into a full-blown systemic autoimmune/rheumatic disease, it is of major importance to assess pathogenic factors leading to this progression. In view of the fact that the serological and clinical picture of UCTD and systemic autoimmune diseases are very similar, it is assumed that analogous pathogenic factors perpetuate both disease entities. In systemic autoimmune conditions, a quantitative and qualitative impairment of regulatory T cells has been shown previously, and in parallel, a relative dominance of pro-inflammatory Th17 cells has been introduced. Moreover, the imbalance between regulatory and Th17 cells plays a pivotal role in the initiation and propagation of UCTD. Additionally, we depict a cytokine imbalance, which give raise to a biased T cell homeostasis from the UCTD phase throughout the fully developed systemic autoimmune disease stage. The levels of interleukin (IL)-6, IL-12, IL-17, IL-23, and interferon (IFN)-γ were pathologically increased with a parallel reduction of IL-10. We believe that the assessment of Th17/Treg cell ratio, as well as the simultaneous quantitation of cytokines may give a useful diagnostic tool at the early UCTD stage to identify patients with a higher chance of consecutive disease progression toward serious systemic autoimmune diseases. Moreover, the early targeted immunomodulating therapy in these patients may decelerate, or even stop this progression, before the development of serious autoimmune conditions with organ damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mosca M, Tani C, Carli L, Bombardieri S (2012) Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol 26:73–77

    Article  CAS  PubMed  Google Scholar 

  2. Mosca M, Tani C, Neri C, Baldini C, Bombardieri S (2000) Undifferentiated connective tissue disease. Autoimmun Rev 6:1–4

    Article  Google Scholar 

  3. Williams HJ, Alarcon GS, Neuner R et al (1998) Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. J Rheumatol 25:261–268

    CAS  PubMed  Google Scholar 

  4. Alarcon GS (2000) Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol 14:125–137

    Article  CAS  PubMed  Google Scholar 

  5. Williams HJ, Alarcon GS, Joks R et al (1999) Early undifferentiated connective tissue disease (CTD) VI: an inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26:816–825

    CAS  PubMed  Google Scholar 

  6. LeRoy EC, Maricq HR, Kahaleh MB (1980) Undifferentiated connective tissue syndromes. Arthritis Rheum 23:341–343

    Article  CAS  PubMed  Google Scholar 

  7. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity–autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259–A266

    Article  CAS  PubMed  Google Scholar 

  8. Abbas AK, Lohr J, Knoechel B, Nagabhushanam V (2004) T cell tolerance and autoimmunity. Autoimmun Rev 3:471–475

    Article  CAS  PubMed  Google Scholar 

  9. Davies AJ (2008) Immunological tolerance and the autoimmune response. Autoimmun Rev 7:538–543

    Article  CAS  PubMed  Google Scholar 

  10. Ermann J, Fathman CG (2001) Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2:759–761

    Article  CAS  PubMed  Google Scholar 

  11. Cooper GS, Miller FW, Pandey JP (1999) The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 107:693–700

    Article  PubMed Central  PubMed  Google Scholar 

  12. Toda A, Piccirillo CA (2006) Development and function of naturally occurring CD4 + CD25+ regulatory cells. J Leukoc Biol 80:458–470

    Article  CAS  PubMed  Google Scholar 

  13. Barath S, Sipka S, Aleksza M et al (2006) Regulatory T-cells in peripheral blood of patients with mixed connective tissue disease. Scand J Rheumatol 35:300–304

    Article  CAS  PubMed  Google Scholar 

  14. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M (2006) Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117:289–300

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Liu MF, Wang CR, Fung LL, Wu CR (2004) Decreased CD4 + CD25+ T-cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 59:198–202

    Article  PubMed  Google Scholar 

  16. Szodoray P, Papp G, Horvath IF, Barath S, Sipka S, Nakken B, Zeher M (2009) Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol 157:343–349

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Valencia X, Yarboro C, Illei G, Lipsky PE (2007) Deficient CD4 + CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178:2579–2588

    Article  CAS  PubMed  Google Scholar 

  18. Szodoray P, Nakken B, Barath S, Gaal J, Aleksza M, Zeher M et al (2008) Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. Int Immunol 20:971–979

    Article  CAS  PubMed  Google Scholar 

  19. Lee JH, Wang LC, Lin YT, Yang YH, Lin DT, Chiang BL (2006) Inverse correlation between CD4 regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 117:280–286

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50

    Article  CAS  PubMed  Google Scholar 

  21. Constant SL, Bottomly K (1997) Induction of Th1 and Th2 CD4+ T-cell responses: the alternative approaches. Annu Rev Immunol 15:297–322

    Article  CAS  PubMed  Google Scholar 

  22. Moore KW, de Waal MR, Coffman RL, O'Garra A (2001) Interleukin 10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765

    Article  CAS  PubMed  Google Scholar 

  23. O'Garra A, Arai N (2000) The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 10:542–550

    Article  PubMed  Google Scholar 

  24. Steinman L (2008) A rush to judgment on Th17. J Exp Med 205:1517–1522

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Hwang SY, Kim HY (2005) Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cell 19:180–184

    CAS  Google Scholar 

  27. Shin MS, Lee N, Kang I (2011) Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol 23:444–448

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, Lan JL (2012) The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 21:1385–1396

    Article  PubMed  Google Scholar 

  29. Lin X, Rui K, Deng J, Tian J, Wang X, Wang S, Ko KH, Jiao Z, Chan VS, Lau CS, Cao X, Lu L. Th17 cells play a critical role in the development of experimental Sjogren's syndrome. Ann Rheum Dis. 2014 Feb 26.

  30. Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, Delaleu N, Jonsson R, Centola M (2005) Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117:168–176

    Article  CAS  PubMed  Google Scholar 

  31. Valencia X, Lipsky PE (2007) CD4 + CD25 + FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 3:619–626

    Article  CAS  PubMed  Google Scholar 

  32. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L, Li M (2009) Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60:1472–1483

    Article  PubMed  Google Scholar 

  33. Kawanami T, Sawaki T, Sakai T, Miki M, Iwao H, Nakajima A, Nakamura T, Sato T, Fujita Y, Tanaka M, Masaki Y, Fukushima T, Hirose Y, Taniguchi M, Sugimoto N, Okazaki T, Umehara H (2012) Skewed production of IL-6 and TGFβ by cultured salivary gland epithelial cells from patients with Sjögren's syndrome. PLoS One 7:e45689

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Tournadre A, Miossec P (2012) Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep 14:252–256

    Article  CAS  PubMed  Google Scholar 

  35. Papp G, Horvath IF, Barath S, Gyimesi E, Vegh J, Szodoray P, Zeher M (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142:150–159

    Article  CAS  PubMed  Google Scholar 

  36. Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, Nagy AT, Constantin T, Ponyi A, Nakken B, Danko K (2010) Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 49:1867–1877

    Article  CAS  Google Scholar 

  37. Alex P, Szodoray P, Knowlton N, Dozmorov IM, Turner M, Frank MB, Arthur RE, Willis L, Flinn D, Hynd RF, Carson C, Kumar A, El-Gabalawy HS, Centola M (2007) Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol 25:584–592

    CAS  PubMed  Google Scholar 

  38. Alex P, Szodoray P, Arthur E, Willis L, Hynd R, Flinn D, Centola M (2007) Influence of intraarticular corticosteroid administration on serum cytokines in rheumatoid arthritis. Clin Rheumatol 26:845–848

    Article  PubMed  Google Scholar 

  39. Szodoray P, Alex P, Chappell-Woodward CM, Madland TM, Knowlton N, Dozmorov I, Zeher M, Jarvis JN, Nakken B, Brun JG, Centola M (2007) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 46:417–425

    Article  CAS  Google Scholar 

  40. Osnes LT, Nakken B, Bodolay E, Szodoray P (2013) Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies—novel tool for diagnostics and patient follow-up. Autoimmun Rev 12:967–971

    Article  CAS  PubMed  Google Scholar 

  41. Szodoray P, Alex P, Brun JG, Centola M, Jonsson R (2004) Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 59:592–599

    Article  CAS  PubMed  Google Scholar 

  42. Zeher M. Sjögren's syndrome. In: Sjögren's syndrome and associated disorders Eds.: Margit Zeher and Peter Szodoray. 2006. Research Signpost. Kerala, India, Transworld Research Network. p.p. 1–7

  43. Szodoray P, Nakken B. Selected molecular aspects behind the clinical picture of Sjögren's syndrome. In: Sjögren's syndrome and associated disorders Eds.: Margit Zeher and Peter Szodoray. 2006. Research Signpost. Kerala, India, Transworld Research Network. p.p. 27–49.)

  44. Ciccia F, Guggino G, Giardina A, Ferrante A, Carrubbi F, Giacomelli R, Triolo G (2014) The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome. Expert Rev Clin Immunol 10:533–541

    Article  CAS  PubMed  Google Scholar 

  45. Garcíc-Carrasco M, Font J, Filella X, Cervera R, Ramos-Casals M, Sisó A, Aymamí A, Ballesta AM, Ingelmo M (2001) Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 19:411–415

    PubMed  Google Scholar 

  46. Yao Y, Liu Z, Jallal B, Shen N (2012) Rönnblom L. Type I Interferons in Sjögren's Syndrome, Autoimmun Rev

    Google Scholar 

  47. Jonsson R, Moen K, Vestrheim D, Szodoray P (2002) Current issues in Sjögren's syndrome. Oral Dis 8:130–140

    Article  PubMed  Google Scholar 

  48. Szodoray P, Gal I, Barath S, Aleksza M, Horvath IF, Gergely P Jr, Szegedi G, Nakken B, Zeher M (2008) Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol 37:205–212

    Article  CAS  PubMed  Google Scholar 

  49. Kyriakidis NC, Kapsogeorgou EK, Tzioufas AG (2013) A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms. J Autoimmun S0896–8411:00145–5

    Google Scholar 

  50. Awada A, Nicaise C, Ena S, Schandéné L, Rasschaert J, Popescu I, Gangji V, Soyfoo MS. Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome. Ann Rheum Dis. 2014 Jan 2.

  51. Szodoray P, Horvath IF, Papp G, Barath S, Gyimesi E, Csathy L, Kappelmayer J, Sipka S, Duttaroy AK, Nakken B, Zeher M (2010) The immunoregulatory role of vitamins A, D and E in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 49:211–217

    Article  CAS  Google Scholar 

  52. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576

    CAS  PubMed  Google Scholar 

  53. Lei W, Luo Y, Lei W, Luo Y, Yan K, Zhao S (2009) Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 38:369–374

    Article  CAS  PubMed  Google Scholar 

  54. Horikawa M, Hasegawa M, Komura K, Hayakawa I, Yanaba K, Matsushita T (2005) Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J Investig Dermatol 125:731–737

    Article  CAS  PubMed  Google Scholar 

  55. Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T (2005) Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol 32:283–286

    CAS  PubMed  Google Scholar 

  56. Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A (2010) Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 261:77–80

    Article  CAS  PubMed  Google Scholar 

  57. Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, Forsea AM (2009) Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 42:41–49

    Article  CAS  PubMed  Google Scholar 

  58. Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K (2008) Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 50:240–242

    Article  CAS  PubMed  Google Scholar 

  59. Deleuran B, Abraham DJ (2007) Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 3:682–683

    Article  CAS  PubMed  Google Scholar 

  60. Sakkas LI, Platsoucas CD (2004) Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 50:1721–1733

    Article  CAS  PubMed  Google Scholar 

  61. Papp G, Horvath IF, Barath S, Gyimesi E, Sipka S, Szodoray P, Zeher M (2011) Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 40:205–210

    Article  CAS  PubMed  Google Scholar 

  62. Papp G, Barath S, Szegedi A, Szodoray P, Zeher M (2012) The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol 31:1293–1299

    Article  PubMed  Google Scholar 

  63. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR (1972) Mixed connective tissue disease -an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 52:148–159

    Article  CAS  PubMed  Google Scholar 

  64. Sharp GC (1987) Diagnostic criteria for classification of MCTD. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and antinuclear antibodies. Elsevier Science Publishers BV, Amsterdam, pp 23–33

    Google Scholar 

  65. Kasukawa R, Tojo T, Miyawaki S (1987) Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and antinuclear antibodies. Elsevier Science Publishers BV, Amsterdam, pp 41–47

    Google Scholar 

  66. Hameenkorpi R, Ruuska P, Forsberg S, Tiilikainen R, Makitalo R, Hakula M (1993) More evidence of distinctive features of mixed connective tissue disease. Scand J Rheumatol 22:63–68

    Article  CAS  PubMed  Google Scholar 

  67. Smolen JS, Steiner G (1998) Mixed connective tissue disease: to be or not to be? Arthritis Rheum 41:768–777

    Article  CAS  PubMed  Google Scholar 

  68. Hoffman RW, Greidinger EL (2000) Mixed connective tissue disease. Curr Opin Rheumatol 12:386–390

    Article  CAS  PubMed  Google Scholar 

  69. Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14:111–124

    Article  CAS  PubMed  Google Scholar 

  70. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC (1999) Long-term outcome in mixed connective tissue disease. Arthritis Rheum 42:899–909

    Article  CAS  PubMed  Google Scholar 

  71. Bodolay E, Aleksza M, Antal-Szalmás P, Végh J, Szodoray P, Soltész P, Szegedi A, Szekanecz Z (2002) Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol 29:2136–2142

    CAS  PubMed  Google Scholar 

  72. Baráth S, Sipka S, Aleksza M, Szegedi A, Szodoray P, Végh J, Szegedi G, Bodolay E (2006) Regulatory T cells in peripheral blood of patients with mixed connective tissue disease. Scand J Rheumatol 35:300–304

    Article  PubMed  Google Scholar 

  73. Hajas A, Szodoray P, Barath S, Sipka S, Rezes S, Zeher M, Sziklai I, Szegedi G, Bodolay E (2009) Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol 36:1930–1936

    Article  CAS  PubMed  Google Scholar 

  74. Hajas A, Sandor J, Csathy L, Csipo I, Barath S, Paragh G, Seres I, Szegedi G, Shoenfeld Y, Bodolay E (2011) Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 10:317–324

    Article  CAS  PubMed  Google Scholar 

  75. Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365:2110–2121

    Article  CAS  PubMed  Google Scholar 

  76. Merola J, Bermas B, Lu B, Karlson E, Massarotti E, Schur P, Costenbader K. Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. Lupus. 2014 Mar 7.

  77. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, James JA (2007) Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 56:2344–2351

    Article  CAS  PubMed  Google Scholar 

  78. Aringer M, Smolen JS (2004) Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13:344–347

    Article  CAS  PubMed  Google Scholar 

  79. Rönnblom L, Elkon KB (2010) Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 6:339–347

    Article  PubMed  Google Scholar 

  80. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK (2008) Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 58:2481–2487

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  81. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB (2009) Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 182:34–38

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Vereecke L, Beyaert R, van Loo G (2009) The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 30:383–391

    Article  CAS  PubMed  Google Scholar 

  83. Munroe ME, Vista ES, Guthridge JM, Thompson LF, Merrill JT, James JA. Pro-inflammatory adaptive cytokines and shed tumor necrosis factor receptors are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol. 2014 Feb 27

  84. Barath S, Aleksza M, Tarr T, Sipka S, Szegedi G, Kiss E (2007) Measurement of natural (CD4 + CD25high) and inducible (CD4 + IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 16:489–496

    Article  CAS  PubMed  Google Scholar 

  85. Barath S, Soltesz P, Kiss E, Aleksza M, Zeher M, Szegedi G, Sipka S (2007) The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4 + CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 40:521–528

    Article  CAS  PubMed  Google Scholar 

  86. Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, Scheinecker C (2008) Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 20:861–868

    Article  CAS  PubMed  Google Scholar 

  87. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW (2008) Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 127:385–393

    Article  CAS  PubMed  Google Scholar 

  88. Wong CK, Ho CY, Li EK, Lam CW (2000) Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9:589–593

    Article  CAS  PubMed  Google Scholar 

  89. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Berard N (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10:778–785

    Article  CAS  PubMed  Google Scholar 

  90. Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S, Valentini V, Riccardi C, Gerli R (2012) Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol 2012:823085

    Article  PubMed Central  PubMed  Google Scholar 

  91. Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, Szücs G, Dankó K, Szegedi G (2003) Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 21:313–320

    CAS  PubMed  Google Scholar 

  92. Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S (2014) The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun 48–49:50–52

    Article  PubMed  Google Scholar 

  93. Mosca M, Tani C, Talarico R, Bombardieri S (2011) Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases. Autoimmun Rev 10:256–258

    Article  PubMed  Google Scholar 

  94. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, Barros R, Santos MJ, Sousa E, Barcelos A, Inês L (2009) Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol 28:915–921

    Article  CAS  PubMed  Google Scholar 

  95. Szodoray P, Nakken B, Barath S, Csipo I, Nagy G, El-Hage F, Osnes LT, Szegedi G, Bodolay E (2013) Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders. Hum Immunol 74:1510–1518

    Article  CAS  PubMed  Google Scholar 

  96. Zold E, Szodoray P, Kappelmayer J, Gaal J, Csathy L, Barath S, Gyimesi E, Hajas A, Zeher M, Szegedi G, Bodolay E (2010) Impaired regulatory T-cell homeostasis due to vitamin D deficiency in undifferentiated connective tissue disease. Scand J Rheumatol 39:490–497

    Article  CAS  PubMed  Google Scholar 

  97. Zold E, Szodoray P, Nakken B, Barath S, Kappelmayer J, Csathy L, Hajas A, Sipka S, Gyimesi E, Gaal J, Barta Z, Hallay J, Szegedi G, Bodolay E (2011) Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev 10:155–162

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Immunology, Rikshospitalet, Oslo University Hospital, Sognsvannsveien 20, Oslo, Norway, N-0027

    Britt Nakken & Peter Szodoray

  2. Department of Clinical Immunology, Institute of Medicine, University of Debrecen Medical and Health Science Centre, Debrecen, Hungary

    Edit Bodolay

Authors
  1. Britt Nakken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edit Bodolay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Szodoray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Szodoray.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakken, B., Bodolay, E. & Szodoray, P. Cytokine Milieu in Undifferentiated Connective Tissue Disease: a Comprehensive Review. Clinic Rev Allerg Immunol 49, 152–162 (2015). https://doi.org/10.1007/s12016-014-8452-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-014-8452-9

Keywords

Search

Navigation